PTCT supply chain intelligence for PTC Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| AKCEA | AKCEA | 92% | Pursuant to the Tegsedi-Waylivra Agreement, we have entered into a master supply agreement with Akcea whereby Akcea or its affiliates will manufacture and supply, or cause to be manufactured and supp… |
| ROCHE | ROCHE | 90% | the License and Collaboration Agreement, dated as of November 23, 2011, by and among the Company, F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc. (together with F. Hoffman-La Roche Ltd, “Roche”), and,… |
| THIRD-PARTY-LOGISTIC-PROVIDERS | THIRD-PARTY-LOGISTIC-PROVIDERS | 90% | We have engaged with third-party logistic providers, or 3PLs, which distribute Translarna for the majority of our commercial and EAP programs on our behalf. |
| SPECIALTY-PHARMACIES | SPECIALTY-PHARMACIES | 85% | The specialty pharmacies provide us with third-party call center services to provide patient support and financial services, prescription intake and distribution, reimbursement adjudication, and ongo… |
| IONS | Ionis Pharmaceuticals, Inc. | 72% | Reciprocal relationship from IONS graph: Reciprocal relationship from PTCT graph: Reciprocal relationship from IONS graph: Reciprocal relationship from PTCT graph: rmaceutical products for which mark… |
| IONS | Ionis Pharmaceuticals, Inc. | 72% | rmaceutical products for which marketing authorization has been granted are subject to extensive and rigorous regulation; ● Failure to obtain and maintain acceptable pricing and reimbursement terms f… |
| KROS | Keros Therapeutics, Inc. | 72% | Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirement… |
| LXEO | Lexeo Therapeutics, Inc. | 72% | Reciprocal relationship from LXEO graph: Reciprocal relationship from PTCT graph: Reciprocal relationship from LXEO graph: s, obtain marketing approval and ultimately commercialize them. If we are un… |
| NVSEF | Novartis AG | 72% | rmaceutical products for which marketing authorization has been granted are subject to extensive and rigorous regulation; ● Failure to obtain and maintain acceptable pricing and reimbursement terms f… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from PTCT graph: rmaceutical products for which marketing authorization has been granted are subject to extensive and rigorous regula… |
| TRDA | Entrada Therapeutics, Inc. | 72% | Reciprocal relationship from TRDA graph: Reciprocal relationship from PTCT graph: Reciprocal relationship from TRDA graph: Reciprocal relationship from PTCT graph: Reciprocal relationship from TRDA g… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| RPI | RPI | 92% | the Company sold to RPI a certain portion of the Company’s right to receive sales-based royalty payments |
| ROCHE | ROCHE | 90% | Under the terms of the SMA License Agreement, Roche acquired an exclusive worldwide license to the Company’s SMA program. |
| HOSPITAL-AND-RETAIL-PHARMACIES | HOSPITAL-AND-RETAIL-PHARMACIES | 80% | Our third-party distributors act as intermediaries between us and end-users and do not typically stock significant quantities of Translarna. |
| SMA-FOUNDATION | SMA-FOUNDATION | 80% | In November 2011, the Company and the SMA Foundation entered into a licensing and collaboration agreement with Roche. |
| IONS | Ionis Pharmaceuticals, Inc. | 72% | rmaceutical products for which marketing authorization has been granted are subject to extensive and rigorous regulation; ● Failure to obtain and maintain acceptable pricing and reimbursement terms f… |
| IONS | Ionis Pharmaceuticals, Inc. | 72% | Reciprocal relationship from IONS graph: Reciprocal relationship from PTCT graph: rmaceutical products for which marketing authorization has been granted are subject to extensive and rigorous regulat… |
| LXEO | Lexeo Therapeutics, Inc. | 72% | Reciprocal relationship from LXEO graph: ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reaso… |
| NVSEF | Novartis AG | 72% | nion of the CHMP of the EMA to not renew the authorization of Translarna for the treatment of nmDMD. This change in estimate for sales allowance resulted in an increase of $98.6 million to the sales … |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from PTCT graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from PTCT graph: Reciprocal relationship from NVSE… |
| TRDA | Entrada Therapeutics, Inc. | 72% | Reciprocal relationship from TRDA graph: everal risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for sub… |
| AGILIS-BIOTHERAPEUTICS-INC | AGILIS-BIOTHERAPEUTICS-INC | 62% | ances as well as publicly available data for instruments with similar characteristics when calculating its incremental borrowing rates. The lease term for all of the Company’s leases includes the non… |
| AKCEA-THERAPEUTICS-INC | AKCEA-THERAPEUTICS-INC | 62% | . If the EC adopts the negative opinion, Translarna would no longer have marketing authorization in the member states of the EEA. The marketing authorization for Translarna remains in effect, pending… |
| CATALYST-PHARMS-INC | CATALYST-PHARMS-INC | 62% | imbursement to be provided for Emflaza are made on a plan-by-plan, and in some cases, on a patient-by-patient basis. Coverage and reimbursement decisions by third-party payors, including the processi… |
| CHEISI-FARMACEUTICA-INC | CHEISI-FARMACEUTICA-INC | 62% | patients. Our ability to generate and realize revenue in Russia may be materially and adversely impacted as many countries, including the United States, have imposed and may continue to consider impo… |
| CHESI-FARMACEUTICA-INC | CHESI-FARMACEUTICA-INC | 62% | patients. Our ability to generate and realize revenue in Russia may be materially and adversely impacted as many countries, including the United States, have imposed and may continue to consider impo… |
| COMPANY-AGILITY-MERGER-SUB-INC | COMPANY-AGILITY-MERGER-SUB-INC | 62% | ances as well as publicly available data for instruments with similar characteristics when calculating its incremental borrowing rates. The lease term for all of the Company’s leases includes the non… |
| HOPEWELL-CAMPUS-OWNER-LLC | HOPEWELL-CAMPUS-OWNER-LLC | 62% | aspects of the Warren Lease dated as of May 24, 2022 between the Company and the Warren Landlord. Pursuant to the Warren Lease Amendment, as of the Surrender Effective Date (as defined in the Warren … |
| NOVARTIS-PHARMACEUTICALS-CORPORATION | NOVARTIS-PHARMACEUTICALS-CORPORATION | 62% | finalize pricing and reimbursement negotiations with the applicable government body in such country. As a result, our commercial launch will continue to be on a country-by-country basis. We also have… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| PTCT-DEBT-PTCT-1-50-CONVERTIBLE-SENIOR-NOTES-DUE-SEPTEMBER-15-2026-2026-09-15 | 1.50% Convertible Senior Notes due September 15, 2026 | 94% | 1.50% convertible senior notes due September 15, 2026. Listed in 10-K 2026-02-19. |
| PTCT-DEBT-11932 | Warrants outstanding: 0 | 90% | xbrl warrant detail from xbrl 2018-12-31. |
| PTCT-DEBT | Debt stack $2.7B | 90% | Market cache reports total debt of $2.7B. |
| PTCT-DEBT-11933 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2020-09-30. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| PTCT-OWNER-JANUS-HENDERSON-GROUP-PLC | JANUS HENDERSON GROUP PLC | 90% | 13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 354 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| ARWR | Arrowhead Pharmaceuticals, Inc. | 100.00 | 2 | |
| SLGL | Sol-Gel Technologies Ltd. | 100.00 | 2 | |
| ELVN | Enliven Therapeutics, Inc. | 100.00 | 2 | |
| ABT | Abbott Laboratories | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 100.00 | 2 | |
| CPMV | Mosaic ImmunoEngineering, Inc. | 100.00 | 2 | |
| SDGR | Schrödinger, Inc. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| BCYC | Bicycle Therapeutics plc | 100.00 | 2 | |
| DYN | Dyne Therapeutics, Inc. | 100.00 | 2 | |
| CAPR | Capricor Therapeutics, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| BMRN | BioMarin Pharmaceutical Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| COLL | Collegium Pharmaceutical, Inc. | 100.00 | 2 |